[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Urological Research Network, LLC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":126},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,84,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100492932","tranberg-transperineal-mrus-fusion-laser--induced-thermal-therapy-for-men-with-prostate-cancer-100492932",false,"NCT05698576","TRANBERG® Transperineal MR\u002FUS Fusion Laser--Induced Thermal Therapy for Men With Prostate Cancer","TRANBERG® Transperineal MR\u002FUS Focalyx Fusion Laser--Induced Thermal Therapy in the Office Setting Under Local Anesthesia","TPF-LITT","Inclusion Criteria:\n\n* Willing and able to sign informed consent\n* Subject is able and willing to complete all procedure and follow-up visits indicated in the protocol\n* Absence of urinary retention\n* Prostate volume: ≥ 18 and ≤ 100 cc, measured by transrectal ultrasound\n* Serum creatinine levels \\\u003C2 ng\u002Fdl and GFR \\> 45\n* Serum PSA levels \\\u003C 20 ng\u002Fml\n* Multiparametric prostate MRI with piRADS scores 3-5\n* Prostate volume: ≥ 18 and ≤ 100 cc, measured by MRI\n* Presence of Intermediate risk prostate cancer with a volume that is less than 1\u002F3 of the gland volume by MRI evaluation\n\nExclusion Criteria:\n\n* Post-void residual (PVR): \\> 250 mL or \\> 50% of voided volume\n* Previous prostate cancer intervention (Radiation therapy, brachytherapy, prostate cryoablation\n* Major neurological conditions such as Alzheimer's, Parkinson, Multiple sclerosis, ALS, spinal cord injury\n* Evidence of neurogenic bladder determined by urodynamics studies\n* Presence of Indwelling Foley catheter or on active regime of clean intermittent catheterization (CIC) in the prior 30 days\n* Active urinary tract infection determined by urinary cultures\n* SHIM score \\\u003C14\n* IPSS score \\>23\n* Acute prostatitis\n* Macroscopic hematuria without a known contributing factor\n* History of colorectal carcinoma with anterior perineal resection of rectum\n* History of pelvic radiation therapy or radical pelvic surgery\n* History of bladder neck contracture and\u002For urethral strictures within the 5 years prior to the informed consent date\n* Bladder stones\n* Medical contraindication for undergoing TPFLA surgery (eg, infection, coagulopathy, significant cardiac or other medical risk factors for surgery)\n* Diagnosed or suspected bleeding or coagulopathic disorder such as hemophilia, ITP, TTP\n* Medical contraindication to being subjected to local anesthesia",true,"MALE","50 Years","80 Years",{"count":22,"type":23},20,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study is set up as a phase I prospective, single center, device interventional pilot study carried in office setting under local anesthesia. It will assess the tolerance and safety of target fusion ablation of prostate cancer tumors using Laser Induced Thermal Therapy (TFA-LITT) guided by fusion imaging in men 50 to 80 years of age with low to intermediate risk prostate cancer\n\nProstate Cancer is currently managed with in a discrete fashion where patients either enroll in active surveillance protocols (No intervention) or undergo full intervention via whole gland treatments - most commonly radical surgery or radiation. These treatments have not shown definitive gains in all cause survival and not uncommonly harbor undesirable adverse effects, most notably: impotency and incontinence. Such events elicit significant and noticeable changes on a male lifestyle and for most prostate cancer tumors are considered overtreatment. This study aims to evaluate the use of TFA-LITT in the office setting under local anesthesia - greatly decreasing patient perioperative surgical risk - focused on the organ sparing cancer lesion ablation, where organ function is preserved.\n\nThe fundamental objective is to determine the tolerance and safety of TFA-LITT in men with low to intermediate risk prostate cancer, successful performed in the outpatient office-based setting under local anesthesia directed by fusion imaging. Secondary objectives include: 1-Biopsy proven cancer control of ablated areas 12 months after procedure; 2-Uroflowmetry and urinary function Patient Reported Outcome Measures (PROMs) at one, three, six, nine and 12 months; 3- Sexual function Patient Reported Outcome Measures (PROMs) at one, three, six, nine and 12 months; 4- MRI changes of ablated area one, three and 12 months after TFA-LITT; 5- Absence or presence of ejaculation after TFA-LITT.",[29,30,31,32,33,34,35,36,37],"Prostate Cancer","Adverse Effects Surgery","MRI","Ultrasound","Sexual Function Disturbances","Urinary Incontinence","Urinary Function Disorders","Prostate Biopsy","Ablation","RECRUITING","2023-01-24",{"date":41,"type":42},"2023-01-26","ACTUAL",{"date":44,"type":42},"2022-03-16",{"date":46,"type":23},"2033-01-30",{"name":48,"class":49},"Urological Research Network, LLC","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":59,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":50},"100457794","mriultrasound-fusion-guided-laser-ablation-of-prostate-cancer-100457794","NCT05241236","MRI\u002FUltrasound Fusion Guided Laser Ablation of Prostate Cancer","Office Based MRI\u002FUltrasound Guided Prostate Cancer Ablation: Outcomes Registry","MRFLA","Inclusion Criteria:\n\n* Men between 50 and 65 years of age with a clinical diagnosis of prostate cancer with Low or Intermediate risk prostate cancer, and \\\u003C50% positive core rate by prostate lobe\n* Men older than 65 years of age with clinical diagnosis of prostate cancer \\\u003C50% positive core rate by prostate lobe\n* Absence of extra-capsular extension\n* Absence of seminal vesicle invasion\n* Absence of regional or distant metastatic disease\n* Multiparametric MRI of the prostate performed either before the biopsy or \\>10 weeks after prostate biopsy\n* Treated with Cryotherapy of the prostate\n* Treatment based on co-registration between MP-MRI and Prostate Ultrasound\n\nExclusion Criteria:\n\n* Prior treatment of prostate cancer in the form of surgery.\n* Performance status greater than 0 based on ECOG criteria\n* Mental status impairment",{"count":60,"type":23},5000,"10 Years","OBSERVATIONAL","This serves as a registration trial. It aims to record short, intermediate, and long-term outcomes of patients treated with targeted laser ablation of biopsy confirmed prostate cancer. Outcomes will be categorized as: 1- Procedure Related, 2- Perioperative - Adverse Events that may occur within 90 days, 3-Oncologic: Recurrence of cancer in treatment area, de-novo tumors, conversion to radical surgery, radiation or cryoablation, emergence of metastasis, 4- Functional: Sexual and Urinary function following treatment",[65,66],"Neoplasms Prostate","Cancer of the Prostate",[68,69,70,32,31,71,72,73,74,75,76,77],"Prostate","PSA","FUSION","Cancer","Laser","Outcomes","Recurrence","QOL, Quality of Life","Urinary function","Sexual Function",{"date":41,"type":42},{"date":80,"type":42},"2020-11-15",{"date":82,"type":23},"2038-11",{"name":48,"class":49},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":24,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":50},"100456072","cryaoablation-assisted-partial-nephrectomy-a-non-ischemic-approach-100456072","NCT05218811","Cryaoablation Assisted Partial Nephrectomy a Non Ischemic Approach","Cryotherapy and Robotic Assisted Non Ischemic Nephron Sparring Surgery","RCAPN","Inclusion Criteria:\n\n* Patients with ages between 45-90-year-old.\n* Renal tumor ≤ 7 cm in the greatest extension, \\>50% exophitic.\n\nExclusion Criteria:\n\n* Prior renal surgery\n* M1 Disease","ALL","55 Years","65 Years",{"count":96,"type":23},150,[26],"Patients with renal masses eligible to partial nephrectomy often require arterial ischemia to control or prevent blood loss during this surgical procedure. This study aims to determine the safety and efficacy of renal cryoablation at the tumor bed, as a substitute measure or technique vs total or selective arterial renal ischemia.",[100],"Kidney Neoplasms",{"date":41,"type":42},{"date":103,"type":42},"2020-05-15",{"date":105,"type":23},"2041-05-15",{"name":48,"class":49},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":18,"minAge":93,"maxAge":4,"enrollmentInfo":115,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":50},"100238430","mriultrasound-fusion-guided-prostate-cryotherapy-100238430","NCT02381990","MRI\u002FUltrasound Fusion Guided Prostate Cryotherapy","Office Based MRI\u002FUltrasound Guided Prostate Cryotherapy: Outcomes Registry","FIPC","Inclusion Criteria:\n\n* Men between 55 and 65 years of age with a clinical diagnosis of prostate cancer with Low or Intermediate risk prostate cancer, and \\\u003C50% positive core rate by prostate lobe\n* Men older than 65 years of age with clinical diagnosis of prostate cancer \\\u003C50% positive core rate by prostate lobe\n* Absence of extra-capsular extension\n* Absence of seminal vesicle invasion\n* Absence of regional or distant metastatic disease\n* Multiparametric MRI of the prostate performed either before the biopsy or \\>10 weeks after prostate biopsy\n* Treated with Cryotherapy of the prostate\n* Treatment based on co-registration between MP-MRI and Prostate Ultrasound\n\nExclusion Criteria:\n\n* Prior treatment of prostate cancer in the form of surgery.\n* Performance status greater than 0 based on ECOG criteria\n* Mental status impairment",{"count":60,"type":23},"Registration of Prostate Cancer patients undergoing Prostate Cryotherapy guided by Mutiparametric-MRI (MP-MRI) highlighting biopsy confirmed regions. The primary outcome measure is 5 year oncological control. Secondary aim is lack of progression beyond the prostate gland. The aim of intervention is to eradicate prostate cancer disease in the treated area while imposing no or minimal deleterious effects in quality of life.",[65,66],[68,69,70,32,31,71,119,73,74,75,76,77],"Cryotherapy",{"date":41,"type":42},{"date":122,"type":42},"2013-08",{"date":124,"type":23},"2033-08",{"name":48,"class":49},""]